• WHAT IS 505(b)(2)?
  • SERVICES
    • Identify Products
      • Strategic Drug Assessment
      • Pre-IND / Integrated Development Plan
      • Product Ideation
    • Develop Products
      • Nonclinical Testing
      • CMC Development
      • Clinical Studies, Phases I-IV
      • Market Assessment
    • Regulatory Strategy
      • Complex Generics
      • FDA Meetings & Submissions
      • Additional Strategies
  • 505(b)(2) BLOG
  • ABOUT
    • The Company
      • Our History
      • Our Experience
      • Leadership Team
    • Resources
      • Success Stories
      • White Papers
      • Speaking Events & Webinars
    • The Latest
      • Press and News
      • Events
  • CAREERS
  • CONTACT US
  • WHAT IS 505(b)(2)?
  • SERVICES
    • Identify Products
      • Strategic Drug Assessment
      • Pre-IND / Integrated Development Plan
      • Product Ideation
    • Develop Products
      • Nonclinical Testing
      • CMC Development
      • Clinical Studies, Phases I-IV
      • Market Assessment
    • Regulatory Strategy
      • Complex Generics
      • FDA Meetings & Submissions
      • Additional Strategies
  • 505(b)(2) BLOG
  • ABOUT
    • The Company
      • Our History
      • Our Experience
      • Leadership Team
    • Resources
      • Success Stories
      • White Papers
      • Speaking Events & Webinars
    • The Latest
      • Press and News
      • Events
  • CAREERS
  • CONTACT US

Exclusivity GAINs Additional Indications: Advantages of QIDP Designation Paired with 505(b)(2) Strategy

  • Posted by: Jennifer
  • Published on: April 11, 2018

Additional Indications: Advantages of QIDP Designation

The benefits of early strategy for 505(b)(2) drug development programs are numerous, but none as substantial as market exclusivity. Incentives available to sponsors of QIDP include fast track designation, priority review designation, and 5 years of additional market exclusivity.

A recently updated FDA guidance for U.S. antibiotic and antifungal development extends incentives to drugs that prevent or diagnose infections. This allows the expansion of a Qualified Infectious Disease Product (QIDP) designation to include multiple indications for one product, therefore permitting QIDP incentives for each indication. These types of incentives require careful early planning but position a product for maximum benefits once approved.

Exclusivity GAINs Additional Indications: Advantages of QIDP Designation Paired with 505(b)(2) Strategy

The Case for QIDP

As mentioned in a recent blog, Camargo assisted Calla Therapeutics, LLC, in obtaining QIDP designation for MT-001, the company’s innovative vaginal cream drug candidate for the treatment of recurrent vulvovaginitis (RVVC). MT-001 is a 505(b)(2) drug candidate. RVVC is a serious condition caused by a pathogen, Candida species, that is a ‘‘qualifying pathogen’’ that has the potential to pose a serious threat to public health, under section 505E(f) of the FD&C Act (further specified in 21 CFR § 317.2, 2017). There are currently no approved therapies in the United States for RVVC. The local administration of MT-001 offers the application of the drug to the site of infection, where it’s needed while limiting the amount of drug that gets into the systemic circulation which drive the safety and tolerability concerns. Data were available in the published literature that support the premise.

Title VIII of FDASIA, Generating Antibiotic Incentives Now (GAIN), added section 505E of the Food, Drug & Cosmetic Act, providing incentives for the development of antibacterial and antifungal drugs for human use intended to treat serious and life-threatening infections (21 CFR § 317.2, 2017). To counter the threat of antibiotic resistance, the Act provides incentives and additional guidance to pharmaceutical companies developing innovative antibiotic products. Innovative includes both 505(b)1) as well as 505(b)(2) drug candidates. Incentives available to sponsors of QIDP include fast track designation, priority review designation, and 5 years of additional market exclusivity.

The Updates to QIDP

Although law (21 CFR § 317.2, 2017) defines QIDP as antibacterials and antifungals intended to treat serious infections, the FDA now interprets the provision more broadly to include preventive and diagnostic products, as stated in a new FDA draft guidance document (published January 2018). Antibacterial and antifungal drugs intended to prevent or diagnose a serious or life-threatening infection are also eligible for designation as a QIDP. The FDA interprets the phrase “intended to treat a serious or life-threatening infection” in the context of QIDPs in a similar manner to other programs under the FD&C Act. These programs are intended to expedite the development of drugs and biologics to address unmet medical needs. Accordingly, the FDA will consider a drug to be “intended to treat a serious or life-threatening infection” if it is intended to “diagnose, prevent, or treat such an infection.”

Importantly, as the QIDP designation applies to a specific drug product for a specific use for which it is being studied, one drug may receive more than one QIDP designation (e.g., one for treatment and one to prevent or diagnose).

Multiple QIDP Indications

That is exactly what Camargo did for our client Calla Therapeutics, LLC. Calla received notification on Friday, March 30, 2018, that the FDA has granted a second QIDP designation to MT-001, to reduce the recurrence of vulvovaginitis. Camargo previously assisted Calla Therapeutics, LLC. in their pursuit for QIDP designation for MT-001, for the treatment of RVVC.

Camargo provided the innovative strategy and regulatory knowledge regarding the requirements and criteria that needed to be met in order to obtain two QIDP designations. As a result, Calla will be positioned to reap the benefits of QIDP designation with not only the additional 5 years marketing exclusivity but also increased communication with the FDA and expedited review of QIDP-designated drug application.

Identify the Incentives

If you have an already approved API (505(b)(2) antibacterial and antifungal drug candidate) to treat or prevent or diagnose a serious condition and address an unmet medical need, multiple QIDP designations may be attainable. Camargo is ready to assist you in the pursuit of exclusivity incentives with our drug development knowledge, exhaustive use of data in the published literature, and innovative strategies.

To learn more about incentive opportunities for your program, contact us.

 

Author:

Stacey Ayres, PhD, Senior Director, Scientific and Regulatory Affairs, Camargo Pharmaceutical Services

Need Help With A Project?

Contact the 505(b)(2) experts at Camargo Pharma about the challenge you are facing with your 505(b)(2) project.

Click Here To Get Help

Need Help?

Contact the 505(b)(2) experts at Camargo Pharma today.

Click Here

Recent Posts
  • The Shutdown From Camargo’s Perspective
  • Scope of Orphan Drug Exclusivity – How Broad is Broad?
  • Market Assessment: Is Your Product Going To Make It On The Market?
Categories
  • 505(b)(2) Development
  • Camargo Counsel
  • Case Study
  • Clinical Studies, Phases I-IV
  • CMC
  • Combination Products
  • Commercialization
  • DESI Drug
  • Device
  • Nonclinical Testing
  • Orphan Drug
  • Prodrug
  • Product Selection and Planning
  • Regulatory Strategy & Submissions
  • Services
  • Therapeutic Areas
  • What Went Wrong?
TRUSTED RESOURCES
  • Center Watch Trial Listing
  • Drugs @ FDA
  • Electronic Orange Book
  • FDA Dockets Home Page
  • US Patent & Trademark Access

camargo pharma

Camargo Pharmaceutical Services provides comprehensive drug development services specialized for the 505(b)(2) approval pathway and analogous European processes.

Headquarters:
9825 Kenwood Road, Suite 203
Cincinnati, OH 45242

Durham Office
2505 Meridian Parkway, Suite 150
Durham, NC 27713

Phone: (513) 561-3329
Toll free: (888) 451-5708
Fax (513) 561-3367

LATEST FROM THE BLOG
  • The Shutdown From Camargo’s Perspective
  • Scope of Orphan Drug Exclusivity – How Broad is Broad?
  • Market Assessment: Is Your Product Going To Make It On The Market?
  • “Breakthrough” the Barriers: Breakthrough Therapy Designation for 505(b)(2)
  • On the “Fast Track”: Fast Track Designations for Your 505(b)(2) Drug Development Program
ADDITIONAL LINKS
  • Home
  • In The News
  • Services
  • 505(b)(2) Blog
  • About Us
  • Camargo Careers
  • Contact Us
© 2019 Camargo | Privacy Policy